Presented at: American Society of Clinical Oncology Annual Meeting 2022
On: Jun 6, 2022
A Phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER
By: K. Jhaveri, R. Jeselsohn, E. Lim, E. Hamilton, K. Yonemori, et. al.